Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00520806 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

A Phase 2 study of Heart Failure, Congestive, sponsored by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies.

Completed
Registry status
Phase 2
Development phase
1,161
Enrollment target
3
Study locations

NCT00520806: Completed Phase 2 study of Heart Failure, Congestive, sponsored by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies.

NCT00520806 is a Phase 2 study of Heart Failure, Congestive that has completed, run by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies. The registered enrollment target is 1,161 participants, above the 645-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (80% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00520806, a Phase 2 study of Heart Failure, Congestive, has completed, sponsored by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies.

COMPLETED
Registry status
Phase 2
Development phase
1,161 participants
Enrollment target
3
Study locations

Study Summary

Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure

Conditions Studied

Heart Failure, Congestive

Interventions

  • DRUG Placebo
  • DRUG Relaxin

Study Locations (3)

Illinois

  • Northwestern University - Chicago

Michigan

  • Wayne State University/Detroit Receiving Hospital - Detroit

Other

  • Heart Institute - Safed

Trial Details

FieldValue
Enrollment Target 1,161 participants
Start Date 2007-10
Est. Completion 2012-09
Phase Phase 2
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

1 total trials

What the finished NCT00520806 record still lists

NCT00520806 is an interventional study that assigns participants to a tested intervention. Its 1,161 participants enrollment target places it among the larger protocols in the corpus, above the 645-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (80% higher).

The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00520806 reports a single indexed study location in Illinois, Michigan, Other.

Frequently Asked Questions

What is clinical trial NCT00520806 about?

NCT00520806 is a clinical study titled "Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure". Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure

What is the current status of trial NCT00520806?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,161 participants. The study started on 2007-10. Estimated completion is 2012-09.

What conditions does trial NCT00520806 study?

This clinical trial studies the following conditions: Heart Failure, Congestive.

What interventions are being tested in trial NCT00520806?

The interventions under investigation include: Placebo (DRUG), Relaxin (DRUG).

Who is sponsoring clinical trial NCT00520806?

This trial is sponsored by Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00520806 being conducted?

This trial has 3 study locations across Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00520806's enrollment target sits among peer trials

1,161 8th of 39 higher than 32 of 39 other Heart Failure, Congestive trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure, Congestive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04577599 · 1,160 participants · NA

    Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

  • NCT07082738 · 1,160 participants · Phase 2

    A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  • NCT07237048 · 1,164 participants · Phase 2

    Minocycline in Stroke Study at Maimonides

  • NCT07009509 · 1,166 participants · NA

    Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00520806, the US trial registry maintained by the National Library of Medicine. NCT00520806 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.